Long COVID Brain Fog Linked to Dopamine Loss

Researchers have identified a potential biological explanation for the persistent "brain fog" experienced by many long COVID patients, linking it to a significant loss of dopamine-releasing nerve terminals in specific brain regions. The study, conducted by researchers at the Centre for Addiction and Mental Health and the University of Toronto, utilized Positron Emission Tomography (PET) imaging to measure levels of Vesicular Monoamine Transporter 2 (VMAT2), a protein found on nerve terminals responsible for releasing dopamine. The research involved 24 individuals diagnosed with long COVID and 24 healthy control subjects who had experienced only mild or moderate initial COVID-19 infections. Published in the journal Nature Medicine, the findings revealed that long COVID patients exhibited substantially lower VMAT2 levels across the striatum, a brain region critical for motivation, movement, and memory. Specifically, the reduction in VMAT2 levels ranged from 16% in the dorsal putamen, a region associated with planning, to 20% in the ventral striatum, which is closely linked to motivation and apathy. Lead researcher Jeffrey Meyer, a psychiatry professor at the University of Toronto, stated that demonstrating these reductions in dopamine-releasing nerves and correlating them with symptoms provides a strong connection to long COVID. This new research builds upon a previous 2023 study by Meyer's team, which detected elevated inflammation in the same brain regions by measuring a different protein associated with inflammatory cells. Meyer suggested that these two findings might be interconnected, with inflammatory cells potentially damaging dopamine-releasing nerve endings, or conversely, nerve injury itself triggering inflammation. The current study's strength lies in the precise correlation observed between the PET imaging results and specific patient symptoms, offering a tangible biological marker for a condition previously defined by subjective patient reports. The implications of this discovery are significant for the millions affected by long COVID, potentially paving the way for more targeted and effective therapeutic interventions. Previously, treatment for long COVID symptoms like fatigue, memory lapses, and lack of motivation has been challenging due to the absence of clear physical markers, leading to difficulties in workplace accommodations and overall patient care. The identification of dopamine loss offers a concrete avenue for developing treatments aimed at restoring dopamine function or mitigating the underlying causes of its depletion. Further research is anticipated to explore the precise mechanisms driving this dopamine loss and to test potential treatments designed to address this newly identified biological deficit.